Ingmar Hoerr, PhD, MBA, is the Chairman of the Supervisory Board of CureVac AG. He founded the biopharmaceutical company in 2000 together with colleagues in Tuebingen, Germany. Today, CureVac is one of the few "unicorn" life sciences companies from Germany. The company is currently valued at Euro 1.5 billion. Since Dr. Hoerr founded CureVac, he raised approximately $430 million (€400 million) in equity investments.
Dr. Hoerr's entrepreneurship was motivated by his surprising discovery during his doctoral research that naked mRNA is capable to be expressed in vivo without the risk of rapid degradation and the ability of generating strong specific immune responses, in contrary to what had previously been believed. From this key discovery, Ingmar Hoerr, Steve Pascolo and Florian von der Muelbe built up a company that is now the most advanced company in the research and development of mRNA-based drugs.
CureVac has worldwide the longest and most extensive experience in handling and optimizing the versatile molecule RNA for medical purposes. The company already has several candidates in R&D for the treatment of cancer, the protection against infectious diseases and for protein replacement. CureVac has tested its mRNA-based products in eight clinical studies with about 450 human patients and healthy volunteers.
CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Boehringer Ingelheim, Eli Lilly, Sanofi Pasteur and the Bill & Melinda Gates Foundation.